EDIT - Editas Medicine, Inc.

QQQ $ 443.34 $ -1.43 (-0.32 %)

DIA $ 393.96 $ -1.13 (-0.28 %)

SPY $ 520.63 $ -1.55 (-0.3 %)

TLT $ 90.74 $ 0.13 (0.14 %)

GLD $ 217.90 $ 0.06 (0.03 %)

Previous Close

$ 5.71

Open

$ 5.91

Bid

$ 5.70 x 200

Ask

$ 5.71 x 200

Day's Range

$ 5.69 - $ 5.92

52 Week Range

$ 4.91 - $ 11.91

Volume

1,925,180

Average Volume

Market Cap

467.87M

Beta (5Y Monthly)

$ 1.51

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-08-2024	03-31-2024	10-Q
2	02-28-2024	12-31-2023	10-K
3	11-03-2023	09-30-2023	10-Q
4	08-02-2023	06-30-2023	10-Q
5	05-05-2023	03-31-2023	10-Q
6	02-22-2023	12-31-2022	10-K
7	11-02-2022	09-30-2022	10-Q
8	08-03-2022	06-30-2022	10-Q
9	05-04-2022	03-31-2022	10-Q
10	02-24-2022	12-31-2021	10-K
11	11-09-2021	09-30-2021	10-Q
12	08-05-2021	06-30-2021	10-Q
13	05-06-2021	03-31-2021	10-Q
14	02-26-2021	12-31-2020	10-K
15	11-06-2020	09-30-2020	10-Q
16	08-07-2020	06-30-2020	10-Q
17	05-08-2020	03-31-2020	10-Q
18	02-26-2020	12-31-2019	10-K
19	11-12-2019	09-30-2019	10-Q
20	08-07-2019	06-30-2019	10-Q
21	05-08-2019	03-31-2019	10-Q
22	03-01-2019	12-31-2018	10-K
23	11-08-2018	09-30-2018	10-Q
24	08-07-2018	06-30-2018	10-Q
25	05-04-2018	03-31-2018	10-Q
26	03-08-2018	12-31-2017	10-K
27	11-08-2017	09-30-2017	10-Q
28	08-09-2017	06-30-2017	10-Q
29	05-15-2017	03-31-2017	10-Q
30	03-03-2017	12-31-2016	10-K
31	11-09-2016	09-30-2016	10-Q
32	08-10-2016	06-30-2016	10-Q
33	05-13-2016	03-31-2016	10-Q
34	03-30-2016	12-31-2015	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Editas Medicine To Present Clinical Data F...
05/14/2024 14:10:26

Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one o...

Editas Medicine Reports Presentation Of Pr...
05/10/2024 10:06:44

The Company will report these data later today in an oral presentation at Annual Meeting of the American Society of Gene and Ce...

Citigroup Maintains Buy on Editas Medicine...
05/09/2024 18:05:16

Citigroup analyst Samantha Semenkow maintains Editas Medicine (NASDAQ:EDIT) with a Buy and lowers the price target from $16 ...

Morgan Stanley Upgrades Editas Medicine to...
05/09/2024 16:41:38

Morgan Stanley analyst Matthew Harrison upgrades Editas Medicine (NASDAQ:EDIT) from Underweight to Equal-Weight and announce...

Barclays Maintains Equal-Weight on Editas ...
05/09/2024 15:05:39

Barclays analyst Gena Wang maintains Editas Medicine (NASDAQ:EDIT) with a Equal-Weight and lowers the price target from $11 ...

Editas Medicine Q1 2024 Adj EPS $(0.76) Mi...
05/08/2024 11:04:15

Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0...

Editas Medicine Announced A Two-year Exten...
05/01/2024 12:09:34

Under the collaboration, Bristol Myers Squibb has opted into 13 different programs across 11 gene targets to date. Two programs...

Editas Medicine To Present Pre-Clinical Da...
04/22/2024 20:33:55

Editas Medicine presentations at ASGCT include:Oral presentation of in vivo pre-clinical data from mouse studies using lipid na...

The Latest Analyst Ratings For Editas Medi...
02/29/2024 17:00:24

Citigroup Maintains Buy on Editas Medicine...
02/29/2024 16:57:18

Citigroup analyst Samantha Semenkow maintains Editas Medicine (NASDAQ:EDIT) with a Buy and raises the price target from $11 ...

Barclays Maintains Equal-Weight on Editas ...
02/29/2024 13:44:38

Barclays analyst Gena Wang maintains Editas Medicine (NASDAQ:EDIT) with a Equal-Weight and raises the price target from $10 ...

why-bumble-shares-are-trading-lower-by-12-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Why Bumble Shares Are Trading Lower By 12%...
02/28/2024 19:02:02

Shares of Bumble Inc. (NASDAQ: BMBL) fell sharply during Wednesday’s session following weak quarterly results.

Advance Auto Parts Reports Q4 Results, Joi...
02/28/2024 16:37:58

U.S. stocks were lower, with the Dow Jones index falling around 100 points on Wednesday.

Editas Medicine Q4 EPS $(0.23) Beats $(0.5...
02/28/2024 12:02:34

Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.5...

Earnings Scheduled For February 28, 2024
02/28/2024 11:24:02

Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenu...

JP Morgan Maintains Neutral on Editas Medi...
02/27/2024 18:02:22

JP Morgan analyst Brian Cheng maintains Editas Medicine (NASDAQ:EDIT) with a Neutral and raises the price target from $8 to $9.

Earnings Outlook For Editas Medicine
02/27/2024 18:01:38

Editas Medicine Highlights 2024 Anticipate...
01/08/2024 13:35:45

Anticipated 2024 milestones include: present reni-cel clinical data updates mid-year and year-end, initiate the RUBY clinical t...

Editas Medicine Announced It Entered Into ...
12/13/2023 14:06:09

Vertex Pharmaceuticals to obtain a non-exclusive license for Cas9 for CASGEVY™ (exagamglogene autotemcel) Agreement extends Edi...

The Latest Analyst Ratings for Editas Medi...
12/12/2023 16:00:18